Share this:
May 31, 2018

Researching Gene Therapy for Liver Diseases: Joseph Lillegard, M.D., Ph.D.

By centerforregmedmc

Joseph Lillegard, M.D., Ph.D., is a Regenerative Medicine Minnesota research grant recipient. He is researching gene therapy to fight inborn errors of metabolism of the liver, primarily Hereditary Tyrosinemia Type 1 (HT1), a metabolic disorder caused by an enzyme deficiency. HT1 is a genetic disorder that can lead to liver and kidney failure, and is fatal without treatment. There is no cure. This project aims to develop a lentivirus-mediated gene therapy to treat multiple inborn errors of liver metabolism, with the research in HT1 serving as a model for future studies of other rare liver diseases.

Dr. Lillegard is a supplemental consultant at Mayo Clinic and a pediatric general and thoracic surgeon at Children's Minnesota.

Learn more about Dr. Lillegard’s research in the video below:

Tags: Center for Regenerative Medicine, Dr. Joseph Lillegard, Hereditary Tyrosinemia, liver disease, Mayo Clinic, Medical Research, regenerative medicine, Regenerative Medicine Minnesota, Regenerative Medicine Minnesota, Research, stem cells

Please login or register to post a reply.
Contact Us · Privacy Policy